Esophageal carcinoma that derives from epithelial cells of glandular origin.
1
During the last 30 years, the incidence of oesophageal adenocarcinoma has increased rapidly.
2
Methods: Consecutive patients with oesophageal adenocarcinoma who underwent PET-CT before neoadjuvant chemotherapy and resection were included.
3
Patients with Barrett's oesophagus have an increased risk of developing oesophageal adenocarcinoma and should be kept under surveillance.
4
There are few epidemiological data on the dietary risk factors of Barrett's oesophagus, a precursor of oesophageal adenocarcinoma.
5
The incidence of oesophageal adenocarcinoma (EADC) is rapidly increasing in Western countries and obesity is thought to be a major risk factor.
1
Barrett's esophagus is an important step in the pathway to esophageal adenocarcinoma.
2
Context: The incidence of esophageal adenocarcinoma is rising and has surpassed squamous cell carcinoma.
3
Future studies of trastuzumab in esophageal adenocarcinoma are indicated.
4
Barrett's esophagus (BE) is the principal risk factor for esophageal adenocarcinoma.
5
Barrett's esophagus is the precursor lesion for esophageal adenocarcinoma.
1
Incidence rates for adenocarcinoma of the esophagus and gastric cardia have been rising rapidly.
2
Methods and materials: Patients with adenocarcinoma of the esophagus without distant organ metastases were eligible.
3
Incidence increased for several cancers, including pancreas, kidney, and adenocarcinoma of the esophagus, which are associated with excess weight.
4
Patients and methods: Sixty-one patients with advanced, surgically unresectable, or metastatic squamous cell or adenocarcinoma of the esophagus were treated.
5
A retrospective analysis should compare the two operative approaches, transhiatal or transthoracic resection in patients suffering from adenocarcinoma of the esophagus.
6
Introduction: Even after potentially curative esophagectomy, the majority of patients with adenocarcinoma of the esophagus or gastroesophageal junction die due to cancer recurrence.
7
Conclusions: There were significant differences in the gene profile between patients with adenocarcinoma of the esophagus responding to neoadjuvant chemotherapy compared with nonresponding patients.
8
In summary, tumor uPA content as determined by ELISA appears to be a powerful, independent prognostic factor for survival in adenocarcinoma of the esophagus.
9
Results: Compared to nonneoplastic epithelium, there was a significant increase in YAP cytoplasmic and nuclear localization in high-grade dysplastic epithelium and adenocarcinoma of the esophagus.
10
Results: The median follow-up time for 518 patients was 29.3 months (range 1-149.2); all patients had adenocarcinoma of the esophagus.
11
Adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) has shown a remarkable increase during recent decades.
12
Adenocarcinoma of the esophagus continues to increase in incidence and has become a significant health problem in Western countries.